GlassScriptPhysician profile
Angela Bell
NPI 1457440661
$2,099.39
in general payments reported to CMS, 2019-2025
30 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $461 · 2022: $456 · 2023: $328 · 2024: $484 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $237.64 | 2021-2025 | Rybelsus, Ozempic, Tresiba |
| Amgen INC. | $231.98 | 2021-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $184.50 | 2022-2025 | |
| Abbvie INC. | $152.62 | 2022-2025 | |
| Abbott Laboratories | $151.30 | 2021-2024 | Freestyle Libre 3, Ensite |
| Takeda Pharmaceuticals U.S.A., INC. | $125.34 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $121.39 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Lilly USA, LLC | $106.04 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $94.01 | 2023-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $87.29 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Ge Healthcare | $75.73 | 2022 | |
| Esperion Therapeutics, INC. | $69.28 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $61.10 | 2021-2025 | |
| Medtronic, INC. | $39.66 | 2024-2025 | Intellis Adaptivestim |
| Vanda Pharmaceuticals INC. | $34.52 | 2024 | Hetlioz, Fanapt |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $30.41 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.39 | 2023-2024 | Synjardy, Jardiance, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $28.69 | 2022 | |
| Sanofi-Aventis U.S. LLC | $27.70 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.63 | 2021 | |
| Inspire Medical Systems, INC. | $23.30 | 2025 | Inspire |
| Dexcom, INC. | $23.04 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $21.93 | 2021 | |
| Amarin Pharma, INC. | $19.23 | 2021 | |
| Merck Sharp & Dohme LLC | $18.76 | 2025 | Lagevrio |
| Nevro Corp. | $17.76 | 2022 | |
| Daiichi Sankyo INC. | $15.90 | 2021 | |
| Almatica Pharma LLC | $15.17 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.06 | 2024 | Camzyos |
| Sanofi Pasteur INC. | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.